Dr. Preethi John, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Drexel University College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 562
Licensed in Texas since 2019, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Drexel University College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license S0467 (first issued 2019; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott & White Medical Center- Waxahachie Waxahachie, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 562
- Services billed
- 86,317
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 12,200 | 40 |
| Injection, fosaprepitant, 1 mg | 10,050 | 58 |
| Injection, nivolumab, 1 mg | 5,820 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,527 | 54 |
| Injection, paclitaxel, 1 mg | 5,496 | 31 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,617 | 118 |
| Injection, lanreotide, 1 mg | 1,560 | 11 |
| Injection, palonosetron hcl, 25 mcg | 930 | 77 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 730 | 11 |
| Injection, granisetron hydrochloride, 100 mcg | 570 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Dallas, TX | 321 |
| Anastrozole Other prescribers in Dallas, TX | 277 |
| Tamoxifen Citrate Other prescribers in Dallas, TX | 56 |
| Gabapentin Other prescribers in Dallas, TX | 48 |
| Verzenio (abemaciclib) | 39 |
| Ibrance (palbociclib) | 29 |
| Exemestane | 21 |
| Olanzapine Other prescribers in Dallas, TX | 21 |
| Kisqali (ribociclib succinate) | 16 |
| Duloxetine Hcl Other prescribers in Dallas, TX | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 33 payments worth $2,998 in total to this clinician.
| Lilly USA, LLC | $1,750 |
|---|---|
| Novartis Pharmaceuticals Corporation | $750 |
| AstraZeneca Pharmaceuticals LP | $223 |
| Tempus Ai, Inc | $125 |
| AbbVie Inc. | $53.40 |
| Regeneron Healthcare Solutions, Inc. | $38.75 |
| Stemline Therapeutics Inc. | $22.78 |
| Daiichi Sankyo Inc. | $19.59 |
| Consulting Fee | $1,750 |
|---|---|
| Long term medical supply or device loan | $750 |
| Food and Beverage | $498 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Jan 15, 2025 | Consulting Fee VERZENIO · Oncology | $1,750 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $168,368 in research payments for these studies, mostly to the institutions running them.
- ALI-1201
Puma Biotechnology, Inc. - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.